|
US4925919A
(en)
*
|
1984-04-25 |
1990-05-15 |
Roland Mertelsmann |
Purified interleukin 2
|
|
US5702699A
(en)
*
|
1982-09-23 |
1997-12-30 |
Cetus Corporation |
Process for the recovery of lipophilic proteins
|
|
US4992271A
(en)
*
|
1982-09-23 |
1991-02-12 |
Cetus Corporation |
Formulation for lipophilic IL-2 proteins
|
|
US4853332A
(en)
*
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
|
JPS60118196A
(ja)
*
|
1983-11-30 |
1985-06-25 |
Takeda Chem Ind Ltd |
インタ−フェロンの製造法
|
|
US4569790A
(en)
*
|
1984-03-28 |
1986-02-11 |
Cetus Corporation |
Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
|
|
US4530787A
(en)
*
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
|
US4908433A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Uses of interleukin-2
|
|
US4908434A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Process for preparing purified interleukin-2
|
|
DE3421302A1
(de)
*
|
1984-06-08 |
1985-12-12 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur isolierung und reinigung von (alpha)-interferonen
|
|
US4572798A
(en)
*
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
|
US4748234A
(en)
*
|
1985-06-26 |
1988-05-31 |
Cetus Corporation |
Process for recovering refractile bodies containing heterologous proteins from microbial hosts
|
|
US5248769A
(en)
*
|
1985-06-26 |
1993-09-28 |
Cetus Oncology Corporation |
Process for recovering refractile bodies containing heterologous proteins from microbial hosts
|
|
US4675387A
(en)
|
1985-07-26 |
1987-06-23 |
E. I. Du Pont De Nemours And Company |
Method for extracting protein with organic acid
|
|
US4816440A
(en)
*
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
|
US5183746A
(en)
*
|
1986-10-27 |
1993-02-02 |
Schering Aktiengesellschaft |
Formulation processes for pharmaceutical compositions of recombinant β-
|
|
US5004605A
(en)
*
|
1987-12-10 |
1991-04-02 |
Cetus Corporation |
Low pH pharmaceutical compositions of recombinant β-interferon
|
|
ES2107449T3
(es)
*
|
1990-11-23 |
1997-12-01 |
Roussel Uclaf |
Procedimiento de preparacion de una proteina elegida entre las citoquinas, que comprende al menos un puente disulfuro intramolecular por oxidacion, a un ph inferior a 5,0 de la proteina recombinante reducida correspondiente.
|
|
DE4128319A1
(de)
*
|
1991-08-27 |
1993-03-04 |
Bioferon Biochem Substanz |
Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
|
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
ATE268810T1
(de)
*
|
1995-12-21 |
2004-06-15 |
Genzyme Corp |
Methode zur zellyse
|
|
US7026468B2
(en)
*
|
1996-07-19 |
2006-04-11 |
Valentis, Inc. |
Process and equipment for plasmid purification
|
|
US7807822B2
(en)
|
1996-08-01 |
2010-10-05 |
Robert Bridenbaugh |
Methods for purifying nucleic acids
|
|
CA2348675A1
(en)
|
1997-10-24 |
1999-05-06 |
Warren Dang |
Methods for preparing polynucleotide transfection complexes
|
|
JPH11335392A
(ja)
|
1998-05-26 |
1999-12-07 |
Hsp Kenkyusho:Kk |
可溶性タンパク質の回収方法
|
|
WO2001079444A2
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc |
Albumin fusion proteins
|
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US20030143191A1
(en)
*
|
2001-05-25 |
2003-07-31 |
Adam Bell |
Chemokine beta-1 fusion proteins
|
|
UY27373A1
(es)
*
|
2001-07-09 |
2003-02-28 |
Schering Ag |
Formulaciones de interferón beta-humano
|
|
EP2277888A3
(en)
|
2001-12-21 |
2011-04-27 |
Human Genome Sciences, Inc. |
Fusion proteins of albumin and erythropoietin
|
|
CA2484556A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
KR101271635B1
(ko)
*
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
|
JP2005538717A
(ja)
*
|
2002-09-13 |
2005-12-22 |
ヴァレンティス,インコーポレイテッド |
核酸のプレパラティブスケールの精製のための装置および方法
|
|
EP1594530A4
(en)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
HYBRID PROTEINS OF ALBUMIN
|
|
EP1734988A4
(en)
*
|
2004-03-01 |
2009-08-05 |
Enzon Pharmaceuticals Inc |
INTERFERON BETA-polymer
|
|
US7628920B2
(en)
*
|
2004-04-07 |
2009-12-08 |
Waters Technologies Corporation |
Compositions and methods for separating enantiomers
|
|
DE102004047189A1
(de)
|
2004-09-29 |
2006-04-06 |
Robert Bosch Gmbh |
Sensor zur Ortung metallischer Objekte sowie Verfahren zur Auswertung von Messsignalen eines solchen Sensors
|
|
PL3321359T3
(pl)
|
2005-04-11 |
2021-06-28 |
Horizon Pharma Rheumatology Llc |
Wariantowe postacie oksydazy moczanowej i ich zastosowanie
|
|
KR101288027B1
(ko)
*
|
2006-04-12 |
2013-07-22 |
새비언트 파마수티컬즈 인크. |
양이온 계면활성제를 이용한 단백질 정제 방법
|
|
JP2010513518A
(ja)
*
|
2006-12-19 |
2010-04-30 |
メリマック ファーマシューティカルズ インコーポレーティッド |
多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
|
|
EP2207890A4
(en)
*
|
2007-10-05 |
2010-12-15 |
Barofold Inc |
HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
|
|
ES2525065T3
(es)
|
2008-04-11 |
2014-12-17 |
Merrimack Pharmaceuticals, Inc. |
Ligadores de seroalbúmina humana y sus conjugados
|
|
JP5773366B2
(ja)
|
2008-04-21 |
2015-09-02 |
ティシュー リジェネレイション セラピューティックス、インコーポレイテッド |
生物学的又は化学的作用物質に対する予防又はそれらの治療のために遺伝子改変されたヒト臍帯血管周囲細胞
|
|
KR20110112301A
(ko)
*
|
2008-11-18 |
2011-10-12 |
메리맥 파마슈티컬즈, 인크. |
인간 혈청 알부민 링커 및 그 콘쥬게이트
|
|
EP2440251A4
(en)
*
|
2009-06-09 |
2013-01-16 |
Defyrus Inc |
INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
|
|
AU2010265964B2
(en)
|
2009-06-25 |
2014-09-18 |
Horizon Therapeutics Usa, Inc. |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
|
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
WO2018089808A1
(en)
|
2016-11-11 |
2018-05-17 |
Horizon Pharma Rheumatology Llc |
Combination therapies of prednisone and uricase molecules and uses thereof
|
|
WO2020160325A1
(en)
|
2019-01-30 |
2020-08-06 |
Horizon Pharma Rheumatology Llc |
Reducing immunogenicity to pegloticase
|
|
WO2020160322A1
(en)
|
2019-01-30 |
2020-08-06 |
Horizon Pharma Rheumatology Llc |
Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
|
|
US12269875B2
(en)
|
2023-08-03 |
2025-04-08 |
Jeff R. Peterson |
Gout flare prevention methods using IL-1BETA blockers
|